Syntex (u.s.a.) Inc.

Syva Company

Icon Bioscience, Inc.

Dade Behring Marburg Gmbh

Dade Behring Inc.

Syntex (u.s.a.) Company

Allergan, Inc.

Mae W Hu

Prithipal Singh

Edwin F Ullman

Vernon G Wong

Glenn T Huang

Cheng-I Lin

William S White

Kirk Schulkamp

Vartan E Ghazarossian

Marcel R Pirio

John S Pease

Thomas L Tarnowski

Maureen Laney

Tan Pham

Faina Karasina

James V Freeman

Chen-jung Hsu

Dariush Davalian

Maureen H Beresini

Yi Feng Zheng

Svetlana Alexander

Hshiou-ting Liu

Khaled A Yamout

Donald E Berger, Jr

Floyd W Colvin

The present embodiments provide for simple devices that guide the loading and dispensing of accurate small doses of fluid from standard injection syringes.

Dose guides for injection syringe

The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.

Use of sustained release dexamethasone in post-cataract surgery inflammation

Devices that guide the accurate loading and dispensing of predetermined doses of fluid from injection syringes are disclosed.

The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.

Sustained release formulations for the treatment of intraocular pressure or glaucoma

Sustained release formulations for the treatment of intraocular pressure of glaucoma

Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I may be employed in assays for the determination of an amphetamine and/or a methamphetamine. Immunogenic conjugates of Formula I may be employed to prepare antibodies for an amphetamine and/or for a methamphetamine for use in assays for the determination of an amphetamine and/or a methamphetamine. The enzyme conjugates may also be employed to screen antibodies for use in such methods.

Assays for amphetamine and methamphetamine using stereospecific reagents

A method of measuring the amount of cyclosporin in a sample suspected of containing cyclosporin is disclosed. A method of inactivating interfering cross-reactive material in an assay for measuring the amount of cyclosporin in a sample suspected of containing cyclosporin is also disclosed. Compositions wherein cyclosporin is conjugated to an immunogenic carrier or a label, optionally through a linking group, at an alanine nitrogen atom of the cyclic backbone of cyclosporin are also disclosed. Compositions wherein atiocyclosporin is conjugated, optionally through a linking group, to an immunogenic carrier or a label are also disclosed. Where cyclosporin is conjugated to an immunogenic carrier, the conjugates may be used as immunogens for the preparation of antibodies which are capable of recognizing cyclosporin. Where atiocyclosporin is conjugated to an immunogenic carrier, the conjugates may be used as immunogens for the preparation of antibodies which are capable of recognizing interfering cross-reactive material but substantially incapable of recognizing cyclosporin or cyclosporin-label conjugates. Where cyclosporin is conjugated to a label, the conjugates may be used as part of a signal producing system in cyclosporin assays. Both the antibodies and label conjugates are useful in the disclosed assay methods.

Cyclosporin immunoassay

Nortriptyline functionalized compounds are provided for conjugation to antigenic compositions, particularly poly(amino acids), and enzymes. The antigenic conjugates are employed for the production of antibodies, which find use in immunoassays for the determination of nortriptyline in a sample, while the enzyme conjugates find use in an enzyme assay for the determination of nortriptyline in a sample.

Nortriptyline conjugates to antigenic proteins and enzymes

Methods are disclosed for inactivating interfering binding proteins in a immunoassay for a member of a specific binding pair (sbp). The method comprises including in an assay medium containing a sample suspected of containing an sbp member and an interfering binding protein an effective amount of a water soluble compound having two substituted or unsubstituted phenyl groups linked to a common atom. When the sbp member or its sbp partner has two phenyl groups linked to a common atom, the compound has a number of groups other than hydrogen attached to the phenyl groups and the atom that differs by at least two from the number of such groups on the sbp member. When the sbp member or its sbp partner has two phenyl groups linked to a common atom and the binding protein is not an antibody, the compound has only one group other than hydrogen attached to a phenyl group or the common atom. The methods have particular application in avoiding cross-reactivity of non-analyte materials in a sample with immunochemical reagents used in such assay. The methods have application also in disrupting complexes between an analyte to be determined and other materials so that one can accurately determine the amount of an analyte in a sample.

Geminal diphenyl derivatives and their use in immunoassays

The instant invention is directed toward an immunoassay which can determine the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine by employing at least two conjugates, each comprised of a functionally similar label bound to an amphetamine analog and a methamphetamine analog respectively and an antibody to amphetamine and an antibody to methamphetamine wherein at least one of the antibodies is a monoclonal antibody.

Compositions and methods for determining the presence of amphetamines in

A kit for inactivating interfering binding proteins in a immunoassay for a member of a specific binding pair (sbp). The method comprises including in an assay medium containing a sample suspected of containing an sbp member and an interfering binding protein an effective amount of a water soluble compound having two substituted or unsubstituted phenyl groups linked to a common atom. When the sbp member or its sbp partner has two phenyl groups linked to a common atom, the compound has a number of-groups other than hydrogen attached to the phenyl groups and the atom that differs by at least two from the number of such groups on the sbp member. When the sbp member or its sbp partner has two phenyl groups linked to a common atom and the binding protein is not an antibody, the compound has only one group other than hydrogen attached to a phenyl group or the common atom. The methods have particular application in avoiding-cross-reactivity of non-analyte materials in a sample with immunachemical reagents used in such assay. The methods-have application also in disrupting complexer between an analyte to be determined and other materials to that one can accurately determine the amount of an analyte in a sample.

The present invention describes a class of dyes for use in staining cell samples and methods of making such dyes. A preferred class of dyes known as detergent dyes which possess the ability to stain cells in whole blood and are only slowly leached or lost from the stained cells over time are described. The present invention has application, for example, to blood typing for the determination of the presence of blood group antigens A, B, AB, O, and D (Rh.sub.o) and antibodies to such antigens.

Growing community of inventors

Los Altos Hills, CA, United States of America

Mae W Hu